Compumedics Limited

Compumedics Limited is an Australian medical technology company that designs, manufactures, and markets diagnostic monitoring systems for sleep disorders, neurology, and cardiology. Their product portfolio includes polysomnography (PSG) systems for sleep studies, electroencephalography (EEG) devices for brain monitoring, transcranial Doppler (TOD) equipment for cerebral blood flow assessment, and related software solutions such as Nexus360 for data management and reporting. These systems are used in hospitals, sleep clinics, research laboratories, and outpatient settings to support diagnosis and treatment planning. The company serves healthcare providers in Australia, the United States, Europe, and Asia, distributing its products through a network of direct sales representatives and independent distributors.

Compumedics is distinguished by its focus on integrated diagnostic platforms that combine sleep, neuro, and cardiology data into cohesive workflows for clinicians. The company maintains regulatory compliance with standards such as FDA clearance in the United States and CE marking in Europe, enabling market access across major jurisdictions. As a publicly listed entity on the Australian Securities Exchange (ticker: CMP), Compumedics provides transparency to shareholders and adheres to corporate governance requirements applicable to ASX‑listed companies. In March 2025 the firm disclosed a ransomware attack that triggered unusual activity in its IT network, affecting systems in both Australia and the United States. As a precaution, all servers were taken offline, Australian systems were gradually restored after verification, and some Nexus360 customers remained offline while daily backups of the impacted data were confirmed intact. An independent forensic investigation was launched to determine the scope of any impact on customer data and to ensure systems are secure before normal services resume. The incident has been reported to the Australian Cyber Security Centre, and further notifications will be considered as the investigation progresses.